Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03672292




Registration number
NCT03672292
Ethics application status
Date submitted
11/09/2018
Date registered
14/09/2018
Date last updated
26/06/2023

Titles & IDs
Public title
Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Scientific title
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Secondary ID [1] 0 0
2018-002565-18
Secondary ID [2] 0 0
SCY-078-206
Universal Trial Number (UTN)
Trial acronym
SCYNERGIA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Invasive Pulmonary Aspergillosis 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SCY-078
Treatment: Drugs - Voriconazole
Other interventions - Oral Placebo Tablets

Experimental: SCY-078 plus Voriconazole - Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).
PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks

Placebo Comparator: Voriconazole mono-therapy - Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).
PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).
Treatment duration = minimum 6 weeks/Max 13 weeks


Treatment: Drugs: SCY-078
Oral tablets of SCY-078

Treatment: Drugs: Voriconazole
Voriconazole IV vials or oral tablets

Other interventions: Oral Placebo Tablets
Oral Placebo Tablets matching SCY-078
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse events; discontinuation due to AE; death
Timepoint [1] 0 0
through study completion, an average of 19 weeks
Secondary outcome [1] 0 0
Composite clinical, radiological and mycological response (global response)
Timepoint [1] 0 0
At end of treatment, day 42 and day 84
Secondary outcome [2] 0 0
Death
Timepoint [2] 0 0
At Day 42 and Day 84
Secondary outcome [3] 0 0
Change in serum GMI
Timepoint [3] 0 0
Weeks 1, 2, 4 and 6
Secondary outcome [4] 0 0
Study drug and comparator plasma concentrations
Timepoint [4] 0 0
Through the first 2 weeks of study

Eligibility
Key inclusion criteria
1. Subject is a male or female adult =18 years of age on the day the study informed
consent form (ICF) is signed.

2. Subject has a probable or proven IPA based on the protocol-specified criteria (Section
22.3) that requires antifungal treatment. Note: Subjects with possible IPA may enter
the screening phase of the study but will only be randomized after meeting criteria
for probable or proven IPA.

3. Subject has a result of a serum GMI from a sample obtained within the 96 hours
preceding enrollment into the study (Baseline/Treatment Day 1).

4. Subject has a diagnosis of a hematological malignancy or a myelodysplastic syndrome or
aplastic anemia or has undergone hematopoietic cell transplantation OR

5. Subject who either recently resolved or ongoing neutropenia (neutropenia defined as
absolute neutrophil count < 0.5 x 10?/L [< 500/mm³] for > 10 days), temporally related
to the onset of fungal disease OR

6. Subject who received treatment with other recognized T-cell immunosuppressants (such
as cyclosporine, tacrolimus, monoclonal antibodies or nucleoside analogs) during the
past 90 days including solid organ transplant patients OR

7. Subject with inherited severe immunodeficiency (e.g. chronic granulomatous disease,
severe combined immunodeficiency)

8. Subject has not received more than 4 days (96 hours) of prior mold-active antifungal
therapy for the treatment of the IPA episode in the 7 days preceding enrollment into
the study (Baseline/Treatment Day 1). However, subjects who have received more than 4
days but less than 7 days of prior mold-active antifungal therapy for the treatment of
the IPA episode in the 7 days preceding enrollment into the study may be enrolled but
will require approval from the study medical monitor, who will evaluate each subject
on a case-by-case basis.

9. Subject has an IPA episode that, in the investigator´s judgement, requires antifungal
therapy and may be adequately treated with voriconazole (i.e., the IPA is not a
breakthrough infection while receiving a mold-active azole antifungal [voriconazole,
posaconazole, isavuconazole or itraconazole] that requires therapy with a non-azole
antifungal agent).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subject has a fungal disease with central nervous system involvement suspected at
Screening.

2. Subject is receiving, has received or anticipates to be receiving concomitant
medications that are listed in the prohibited medication list (Appendix A in full
protocol) within the specified washout periods.

3. Subject has a Karnofsky score <20.

4. Subject is expected to die from a non-infectious cause within 30 days from the day the
study ICF is signed.

5. Subject is under mechanical ventilation.

6. Subject has abnormal liver test parameters: AST or ALT >5 x ULN and/or total bilirubin
>2.5 x ULN.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/01/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/03/2023
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Center, 305 Grattan Street - Melbourne
Recruitment hospital [2] 0 0
Alfred Hospital, 55 Commercial Road - Melbourne
Recruitment hospital [3] 0 0
Royal Melbourne Hospital, 300 Grattan Street, Level 9 North - Parkville
Recruitment postcode(s) [1] 0 0
3000 - Melbourne
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
Belgium
State/province [11] 0 0
Brugge
Country [12] 0 0
Belgium
State/province [12] 0 0
Leuven
Country [13] 0 0
Canada
State/province [13] 0 0
Ontario
Country [14] 0 0
Canada
State/province [14] 0 0
Quebec
Country [15] 0 0
Germany
State/province [15] 0 0
Köln
Country [16] 0 0
Mexico
State/province [16] 0 0
Tlalpan
Country [17] 0 0
Mexico
State/province [17] 0 0
Mexico City
Country [18] 0 0
South Africa
State/province [18] 0 0
Gauteng

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Scynexis, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active
azole (voriconazole) compared to voriconazole in patients with invasive pulmonary
aspergillosis.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03672292
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
David Angulo, MD
Address 0 0
Scynexis, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03672292